Market View

The U.S. market is in a Confirmed Uptrend. The S&P 500 and Nasdaq held support along their respective 50-DMA early
this week, before pushing higher on Friday. Both indices are now testing resistance at January 18 intraday highs (S&P 500:
2,675; Nasdaq: 7,185) before a potential move to the 200-DMA. Overall action remains constructive with just one
distribution day on the S&P 500 and zero on the Nasdaq.

Since the follow-through day, five sectors have rallied more than 10%, including Transportation, Consumer Cyclical, and
Technology, which each have rallied more than 11%. Nine of 11 sectors remain above their respective 50-DMA, with only
Utility and Consumer Staple still trading below that level. The rally is broadening, led by industry groups across multiple
sectors including Apparel, Banks, Brokers, Computer Tech Services, Internet, Medical Products, Mortgage Services, Payment
Processors, Rails, Restaurants, Semiconductors, and Software, among others.

Market View

The U.S. market is in a Confirmed Uptrend. The S&P 500 and Nasdaq both regained their respective 50-DMA. We will look
for this level to act as support should the market pullback. The next level of major resistance is the 200-DMA (S&P 500:
2,741 (+2.6%); Nasdaq: 7,451 (+4.1%)). Action remains constructive with just one distribution day on the S&P 500 and
zero on the Nasdaq.

Since the follow-through day, five sectors have rallied more than 10%, including Transportation and Consumer Cyclical,
which each rallied more than 11%. Further, nine of 11 sectors regained their respective 50-DMA, with only Utility and
Consumer Staple still trading below that level. The rally has been broad, led by industry groups across multiple sectors
including Apparel, Banks, Biotech, Brokers, Computer Tech Services, Internet, Medical Products, Mortgage Services, Rails,
Software, and Trucks, among others.

Market View

The U.S. market is in a Confirmed Uptrend. The S&P 500 and Nasdaq made progress since last Friday’s follow-
through day, and are both now testing resistance at their respective 50-DMA (S&P 500: 2,628 (+1.2%);

Nasdaq: 6,988 ( +0.3% )). Though this is an obvious resistance level, we would still like to see the indices close
above this and consolidate for several sessions, which should lead to broader leadership.
Since the follow-through day, Consumer Cyclical, Transportation, Energy, and Technology are leading, each up
more than 7%. Further, Consumer Cyclical and Retail both regained their respective 50-DMA. We are seeing
better technical action, however, just like the major averages, most sectors are also set to hit moving average
resistance over the next several sessions. At the industry group level, Biotech, Computer Tech Services, Electronic
Measuring, Homebuilders, Internet, Medical Equipment, Payment Processors, Rails, Semiconductors, and
Software made notable moves higher.
The number of breakouts is increasing, but most ideas are still rounding out the right side of their respective
bases and have not reached risk-optimal entry points. Since the follow-through day, there were ~20 ideas with
a greater-than-$1B market cap that broke out from consolidation. We will look for more ideas to break out if the
market regains its 50-DMA in the coming days. Ideas we are watching include ADSK, CHGG, CYBR, DXCM,
EPAM, ETSY, FIVE, FIVN, GLOB, HUBS, ISRG, LULU, MEDP, NOW, PANW, RPD, SAVE, SPLK, TSLA, TWLO, ZEN,
and ZS, among others.
We continue to recommend a selective approach, gradually increasing risk in only fundamentally sound ideas
breaking out from consolidation. If the major averages can rise above their respective 50-DMA, there could be
another move higher to the 200-DMA. Should this occur, additional buy opportunities will emerge.
Stocks on our U.S. Focus List: Current Sentiment
Our USFL of 28 ideas gained 4.1% on average this week, outperforming the S&P 500 (+2.5%) and the Nasdaq
( +3.5%. )
Actionable Focus List ideas: Atlassian ( TEAM ), Dorman ( DORM ), Dr. Reddy’s Labs ( RDY ), Fabrinet ( FN ), Keysight
Technologies ( KEYS ), Paypal ( PYPL ), Planet Fitness ( PLNT ), Union Pacific ( UNP ), Veeva Systems ( VEEV ), Vertex
Pharma ( VRTX ), Wingstop ( WING ), Workday ( WDAY ), Wright Medical ( WMGI ), Xilinx ( XLNX ).

Market View

The U.S. market has been upgraded to a Confirmed Uptrend. The S&P 500 staged a day seven follow-through
on Friday, rising 3.4%, on volume 15% greater than Thursday’s. The Nasdaq rose 4.3%, but volume was slightly

less than Thursday’s, despite coming in above the 50-day average. The next level of resistance is the downward-
trending 50-DMA, at 2,637 (+4%) on the S&P 500 and 7,012 (+3.9%) on the Nasdaq.

Growth ideas and industry groups rallied sharply higher, though most continue to repair technical damage from
the last few months. Eight of 11 O’Neil sectors rallied more than 3%, led by Technology and Consumer Cyclical,

both up more than 4%. At the industry group level, Software, Internet, Semiconductors, Payment Processors, Ma-
chinery, and Biotech led. Conversely, defensive sectors lagged, with Consumer Staple and Utility rising less than

2% each.
We believe in order for this follow-through day to develop into a new bull market, growth, not value, needs to

lead. Like the market, growth-oriented industry groups still have multiple resistance levels to regain. Our convic-
tion in this follow-through day will increase as the market rises through resistance, specifically at the 50-DMA.

Further, we need to see leadership broaden and growth ideas begin to break out from consolidation.

Our recommendation is to increase risk gradually, buying only high-quality growth ideas that have either recov-
ered quickly or held up well during this correction. Best-acting ideas on the U.S. Focus List include CIEN, PLNT,

PYPL, XLNX, VEEV, VRTX, and WMGI. Ideas we are watching include AYX, CHGG, DATA, ETSY, FIVN, SPLK,
TEAM, TWLO, WDAY, and ZS, among others. Future leading ideas tend to quickly move back into new highs
within the first three to four weeks of the market bottom.
We will begin adding ideas if the market progresses higher and leadership begins to broaden. As of today, the
majority of stocks are still forming new bases with very few at risk-optimal entry points. We will also monitor for
signs of a failed follow-through day, which include a clustering of distribution days shortly following the move,
coupled with failed breakouts in individual ideas.

Market View

The U.S. market has been moved to a Rally Attempt. Indices are consolidating after Wednesday’s big move

( ~5% ) off lows followed by Thursday’s bullish reversal. We could upgrade the U.S market to a Confirmed Up-
trend as early as Monday should a new follow-through day occur. Currently, the inventory of high quality stocks

with risk optimal entry points is low given the severe technical damage that occurred prior to this week. If a new
follow-through day occurs, we want to see more leadership ideas emerging from constructive consolidations as

risk-on sectors/groups move above price- or moving-average resistance. We recommend waiting for a new fol-
low-through day before increasing risk.

Stocks on our U.S. Focus List: Current Sentiment
Our USFL of 24 ideas gained 3% on average this week, outperforming the S&P 500 (2.8%) but underperforming
the Nasdaq ( 4.0% ).
Actionable Focus List ideas: Ciena ( CIEN ), Dr. Reddy’s Labs ( RDY ), Fabrinet ( FN ), Xilinx ( XLNX )
By Sector

Along with the strong bounce off lows across the major indices, U.S Focus List performance was driven by Tech-
nology, Retail, Health Care, and Financial. In Technology, CIEN and FN regained their 50-DMA, while VEEV

and XLNX bounced off lows and are just below this key moving average. In Retail, WING is forming the right
side of a base after bouncing off its 200-DMA. Four Health Care ideas jumped 3.8% on average, led by ILMN,
but all continue to consolidate in a base. Financial ideas also remain in consolidation after a strong recovery off
lows this week, but PYPL is exhibiting constructive price action as it forms the right side of base, with a potential
aggressive entry at ~$90.

Market View

The U.S. market is in a Downtrend. The S&P 500 and Nasdaq made new year-to-date lows this week in heavy volume. Both have become extended to the downside, trading more than 12% below their respective 200-DMA. Though there are signs of capitulation, we do not recommend increasing risk until we see a new follow-through day. Multiple levels of resistance remain and there are little-to-no growth ideas at proper pivot points. A strong rally off the lows will give us clues as to what could eventually lead, when and if the market has indeed bottomed. At this point, it is too early to tell as ideas are still resetting and will need time to form proper bases. We continue to recommend a cautious approach. Avoid new buys until a new follow through day occurs.

Market View

The U.S. market is in an Uptrend Under Pressure. The S&P 500 and Nasdaq reversed off earlier gains in the week and are again testing support at the October/November lows. Support remains between 2,532 and 2,600 on the S&P 500 and between 6,630 and 6,830 on the Nasdaq. We will downgrade the market to a Downtrend when and if the Nasdaq undercuts 6,830.

This remains a risk-off market. Defensive ideas and groups continue to lead, with few growth ideas acting well. Following Friday’s action, Utility is now the only sector trading above its 50-DMA. Cleaning Products, Food, Beverages, Utility, and Telecom make up the majority of the Top 10 ranked Industry Groups. Further, the action in Banks has been very concerning, with many now testing 2016 highs and erasing all 2017 gains. Our seven Bank Industry Groups are now trading a median of 22% off highs, with the 78 S&P 500 Financial stocks (not including Reits) trading a median of 24% off highs.

We maintain our cautious view of the general market and do not recommend increasing risk until we see better technical action across the major averages, growth-oriented sectors/industry groups, and risk-on ideas. Action remains wide and loose with multiple levels of major resistance to clear before a new constructive trend, higher, can develop.

Market View

The U.S. market is in an Uptrend Under Pressure. The S&P 500 and the Nasdaq reversed off 50 and 200-DMA resistance this week and are again whipsawing back and forth with no clear direction. Should the indices undercut the October lows (S&P 500: 2,603; Nasdaq: 6,830), the November 28 follow-through day will officially fail, resulting in a market downgrade to Downtrend. Conversely, if the S&P 500 and the Nasdaq can rally off the lows, and clear and hold above their respective 50- and 200-DMA, we will move the market status back into a Confirmed Uptrend.

Within the S&P 500, ~65% of stocks are trading below their respective 200-DMA and a median of 24% off highs, indicating poor internal action and a lack of leadership. Eight of 11 O’Neil sectors are also trading below their 200-DMA after failing at that level Tuesday. The three sectors trading above the 200-DMA are Utility, Consumer Staple, and Health Care.

This backdrop warrants a cautious approach. Leadership is thin and breadth is narrow. We need to see indices tighten up and regain moving average support, and leadership broaden before we can recommend increasing risk in a more meaningful way.

Global Health Care Sector: Biotech/Pharma

Some highlights from this report:

  • With its upcoming IPO, Moderna ( MRNA ) will be the largest biotech company to go public, but what’s even more exciting is its work with messenger RNA ( mRNA ) therapeutics and vaccines. These mRNA therapies use a patient’s own cells to prevent, treat, and cure disease, potentially opening an entirely new category of medicine.
  • The iShares Nasdaq Biotech ETF ( IBB ) and the iShares U.S. Pharmaceuticals ETF ( IHE ) have been choppy and rangebound. We continue to recommend a selective approach that focuses on technically intact profitable biotech and pharma companies with underpenetrated and superior FDA-approved drugs.
  • The Indian generic drug market looks set to outperform, with record numbers of FDA approvals that will help them seize advantage of the growing worldwide generic drug market. In North America alone, 70% of the drug market is now generic, up from 52% in 2006.
  • The attached report accompanies Raj Gupta’s webinar on the Best U.S. Biotech and Pharma Ideas in the Health Care sector, on Thursday, December 6, at 11am EST.